TY - JOUR
T1 - Characterization of HER2/neu and topoisomerase IIa status by FISH in locally advanced breast cancer
AU - Mari, Josep
AU - Saez, Berta Laquente
AU - Mayol, Xavier Fabregat
AU - Figueras, Sergio Serrano
AU - Torres, Corominas
AU - Contero, Cristina Corzo
AU - De Bes, Ignacio Tusquets Trias
AU - Galeote, Marta Salido
AU - Ezquerra, Meritxel Bellet
AU - Ristol, Francesc Solé
PY - 2004/1/1
Y1 - 2004/1/1
N2 - Background. HER2/neu encodes a receptor related to breast cancer pathogenesis and topoisomerase IIa is an enzyme involved in response to anthracycline chemotherapy. The aim of this study is to analyse HER2/neu and topoisomerase IIa in a homogenous series of 49 patients with locally-advanced breast cancer (LABC) to determine their status and predictive value with respect to response to treatment. Material and methods. Paraffin-embedded tissues samples from patients with LABC (prior to their neoadjuvant chemotherapy programme) were analysed using the FISH technique. Results. HER2 amplification was noted in 29% of cases of which 77% presented amplification in the topoisomerase IIa gene, 15% had deletion and 8% did not show any aberration in topoisomerase IIa status. Conclusions. These preliminary analyses show a correlation between HER2 amplification and topoisomerase IIa status (92%), and suggest that patients with non-amplified HER2/neu or topoisomerase IIa have better response and have and increase (albeit not statistically significant) in disease- free survival (DFS). However, the limited numbers of patients in the study preclude definitive conclusion regards the value of these genes in predicting patient response to anthracycline-based chemotherapy.
AB - Background. HER2/neu encodes a receptor related to breast cancer pathogenesis and topoisomerase IIa is an enzyme involved in response to anthracycline chemotherapy. The aim of this study is to analyse HER2/neu and topoisomerase IIa in a homogenous series of 49 patients with locally-advanced breast cancer (LABC) to determine their status and predictive value with respect to response to treatment. Material and methods. Paraffin-embedded tissues samples from patients with LABC (prior to their neoadjuvant chemotherapy programme) were analysed using the FISH technique. Results. HER2 amplification was noted in 29% of cases of which 77% presented amplification in the topoisomerase IIa gene, 15% had deletion and 8% did not show any aberration in topoisomerase IIa status. Conclusions. These preliminary analyses show a correlation between HER2 amplification and topoisomerase IIa status (92%), and suggest that patients with non-amplified HER2/neu or topoisomerase IIa have better response and have and increase (albeit not statistically significant) in disease- free survival (DFS). However, the limited numbers of patients in the study preclude definitive conclusion regards the value of these genes in predicting patient response to anthracycline-based chemotherapy.
KW - Locally advanced breast cancer
KW - FISH
KW - Predictive value
KW - Topoisomerase IIa
KW - HER2/neu
UR - https://dialnet.unirioja.es/servlet/articulo?codigo=929968
U2 - 10.1007/BF02711836
DO - 10.1007/BF02711836
M3 - Article
SN - 1699-048X
VL - 6
SP - 289
EP - 294
JO - Clinical and Translational Oncology
JF - Clinical and Translational Oncology
IS - 5
ER -